Citigroup
GMAB icon

Citigroup’s Genmab GMAB Stock Holding History

Citigroup’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$756K Sell
27,531
-3,412
-11% -$90.7K ﹤0.01% 3647
2026
Q1 		$830K Sell
30,943
-7,296
-19% -$219K ﹤0.01% 3241
2025
Q4 		$1.18M Sell
38,239
-60,579
-61% -$1.89M ﹤0.01% 3028
2025
Q3 		$3.03M Buy
98,818
+11,347
+13% +$277K ﹤0.01% 2342
2025
Q2 		$1.81M Buy
87,471
+67,456
+337% +$1.38M ﹤0.01% 2730
2025
Q1 		$392K Buy
20,015
+1,348
+7% +$28.3K ﹤0.01% 3807
2024
Q4 		$390K Sell
18,667
-1,126
-6% -$24.7K ﹤0.01% 4001
2024
Q3 		$483K Sell
19,793
-3,276
-14% -$87.6K ﹤0.01% 3751
2024
Q2 		$580K Buy
23,069
+4,489
+24% +$127K ﹤0.01% 3294
2024
Q1 		$556K Buy
18,580
+1,655
+10% +$48.6K ﹤0.01% 3493
2023
Q4 		$539K Sell
16,925
-4,620
-21% -$145K ﹤0.01% 3354
2023
Q3 		$760K Buy
21,545
+12,863
+148% +$490K ﹤0.01% 2732
2023
Q2 		$330K Buy
8,682
+3,232
+59% +$129K ﹤0.01% 3633
2023
Q1 		$206K Sell
5,450
-19,733
-78% -$758K ﹤0.01% 3716
2022
Q4 		$1.07M Buy
25,183
+20,471
+434% +$843K ﹤0.01% 2557
2022
Q3 		$151K Sell
4,712
-64
-1% -$2.25K ﹤0.01% 3902
2022
Q2 		$156K Sell
4,776
-590
-11% -$19.1K ﹤0.01% 3978
2022
Q1 		$194K Buy
5,366
+8
+0.1% +$275 ﹤0.01% 4097
2021
Q4 		$213K Sell
5,358
-35,016
-87% -$1.46M ﹤0.01% 4328
2021
Q3 		$1.76M Buy
40,374
+22,270
+123% +$1,000K ﹤0.01% 2633
2021
Q2 		$738K Buy
18,104
+7,534
+71% +$291K ﹤0.01% 3446
2021
Q1 		$347K Sell
10,570
-83,410
-89% -$3.14M ﹤0.01% 3711
2020
Q4 		$3.82M Buy
93,980
+5,918
+7% +$221K ﹤0.01% 2282
2020
Q3 		$3.22M Buy
88,062
+1,047
+1% +$37.9K ﹤0.01% 2240
2020
Q2 		$2.95M Buy
87,015
+73,061
+524% +$1.99M ﹤0.01% 2362
2020
Q1 		$296K Sell
13,954
-445
-3% -$9.92K ﹤0.01% 4368
2019
Q4 		$320K Buy
14,399
+11,915
+480% +$260K ﹤0.01% 4801
2019
Q3 		$50K Buy
+2,484
New +$48.9K ﹤0.01% 6125

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's GMAB Position: Q2 2026 in Review

Citigroup reduced its Genmab (GMAB) stake by 11% in Q2 2026, selling an estimated $90.7K and leaving 27,531 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #3647.

Citigroup first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $3.82M in Q4 2020. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Citigroup held 27,531 shares of Genmab worth $756K as of Q2 2026.
  • Citigroup sold 3,412 Genmab shares in Q2 2026, an estimated $90.7K.
  • Genmab made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3647 holding.
  • Citigroup first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Citigroup's Genmab position peaked at $3.82M in Q4 2020.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.